Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru


ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Атмосфера. Новости кардиологии
2022 / N 1

Роль фиксированной комбинации периндоприла и бисопролола в лечении сердечно-сосудистых заболеваний
Г.А. Барышникова, С.А. Чорбинская, Т.А. Зимина, И.И. Степанова

References

1. Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. The Lancet 2015 Aug;386(9995):743-800.
2. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S, Lip GYH, McManus R, Narkiewicz K, Ruschitzka F, Schmieder RE, Shlyakhto E, Tsioufis C, Aboyans V, Desormais I; ESC Scientific Document Group. 2018 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). European Heart Journal 2018 Sep;39(33):3021-104.
3. Ministry of Health of the Russian Federation; Russian Society of Cardiology. Clinical recommendations. Arterial hypertension in adults, 2020. ICD 10 codes: I10/I11/I12/I13/I15. Age group: adults. Moscow, 2020. 136 p. (In Russian).
4. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003 Jun;326(7404):1427-35.
5. Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11 000 participants from 42 trials. The American Journal of Medicine 2009 Mar;122(3):290-300.
6. Gradman AH, Basile JN, Carter BL, Bakris GL; American Society of Hypertension Writing Group. Combination therapy in hypertension. Journal of the American Society of Hypertension 2010 Jan-Feb;4(1):42-50.
7. Liou YS, Ma T, Tien L, Lin CM, Jong GP. The relationship between antihypertensive combination therapies comprising diuretics and/or beta-blockers and the risk of new-onset diabetes: a retrospective longitudinal cohort study. Hypertension Research 2009 Jun;32(6):496-9.
8. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. The American Journal of Medicine 2007 Aug;120(8):713-9.
9. Egan BM, Bandyopadhyay D, Shaftman SR, Wagner CS, Zhao Y, Yu-Isenberg KS. Initial monotherapy and combination therapy and hypertension control the first year. Hypertension 2012 Jun;59 (6):1124-31.
10. World Health Organization Model List of Essential Medicines – 22nd List, 2021. Geneva: World Health Organization; 2021. Available from: http://apps.who.int/iris/handle/10665/345533 Accessed 2022 Jun 27.
11. Prichard B, Cruickshank J, Graham B. Beta-adrenergic blocking drugs in the treatment of hypertension. Blood Pressure 2001;10(5-6):366-86.
12. De la Sierra A, Gorostidi M, Banegas JR, Segura J, Vinyoles E, de la Cruz JJ, Ruilope LM. Ambulatory blood pressures in hypertensive patients treated with one antihypertensive agent: differences among drug. Journal of Clinical Hypertension (Greenwich, Conn.)2015;17(11):857-65.
13. Zhou WJ, Wang RY, Yan Li, Chen DR, Chen EZ, Zhu DL, Gao PJ. Randomized controlled study on the effects of bisoprolol and atenolol on sympathetic nervous activity and central aortic pressure in patients with essential hypertension. PloS One 2013 Sep;8(9):e72102.
14. Boissel JP, Collet JP, Lion L, Ducruet T, Moleur P, Luciani J, Milon H, Madonna O, Gillet J, Gerini P. A randomized comparison of the effect of four antihypertensive monotherapies on the subjective quality of life in previously untreated asymptomatic patients: field trial in general practice. The OCAPI Study Group. Optimiser le choix d’un antihypertenseur de première intention. Journal of Hypertension 1995 Sep;13(9):1059-67.
15. Broncel M, Chojnowska-Jezierska J, Adamska-Dyniewska H. Bisoprolol in the treatment of hypertension in the elderly. Journal of Human Hypertension 1998 Sep;12(9):643-4.
16. Czuriga I, Riecansky I, Bodnar J, Fulop T, Kruzsicz V, Kristof E, Edes I; NEBIS Investigators; NEBIS Investigators Group. Comparison of the new cardioselective beta-blocker nebivolol with bisoprolol in hypertension: the Nebivolol, Bisoprolol Multicenter Study (NEBIS). Cardiovascular Drugs and Therapy 2003 May;17(3):257-63.
17. Lainscak M, Podbregar M, Kovacic D, Rozman J, von Haehling S. Differences between bisoprolol and carvedilol in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized trial. Respiratory Medicine 2011 Oct;105(Suppl 1):S44-9.
18. Kubota Y, Asai K, Furuse E, Nakamura S, Murai K, Tsukada YT, Shimizu W. Impact of β-blocker selectivity on long-term outcomes in congestive heart failure patients with chronic obstructive pulmonary disease. International Journal of Chronic Obstructive Pulmonary Disease 2015 Mar;10:515-23.
19. Haneda T, Ido A, Fujikane T, Tanaka H, Tanazawa S, Morimoto H, Kato J, Kanaya K, Honda H, Sakai H, Akita N, Hirayama T, Onodera S, Kikuchi K. [Effect of bisoprolol, a beta 1-selective beta-blocker, on lipid and glucose metabolism and quality of life in elderly patients with essential hypertension]. Nippon Ronen Igakkai Zasshi 1998 Jan;35(1):33-8.
20. Weir MR, Moser M. Diuretics and β-blockers: is there a risk for dyslipidemia? American Heart Journal 2000 Jan;139(1 Pt 1):174-83.
21. Kollias A, Lagou S, Zeniodi ME, Boubouchairopoulou N, Stergiou GS. Association of central versus brachial blood pressure with target-organ damage: systematic review and meta-analysis. Hypertension (Dallas, Tex., 1979) 2016 Jan;67(1):183-90.
22. McEniery C. Central blood pressure and cardiovascular risk: an individual participant meta-analysis of prospective observational data from 22,433 subjects. Journal of the American College of Cardiology 2015 Mar;65(Suppl 10):A1464.
23. Zeng W, Tomlinson B. Effect of bisoprolol on central aortic systolic pressure in Chinese hypertensive patients after the initial dose and long-term treatment. Bosnian Journal of Basic Medical Sciences 2022;22(3):427-34.
24. A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees. Circulation 1994 Oct;90(4):1765-73.
25. The Cardiac Insufficiency Bisoprolol Study II (CIBIS II): a randomized trial. The Lancet 1999 Jan;353(9146):9-13.
26. Willenheimer R, van Veldhuisen D, Silke B, Erdmann E, Follath F, Krum H, Ponikowski P, Skene A, van de Ven L, Verkenne P, Lechat P; CIBIS III Investigators. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation 2005 Oct;112(16):2426-35.
27. Vanoli E, Dei Cas L, Willenheimer R. Sudden death prevention in heart failure: the case of CIBIS III. Heart International 2006;2(2):73.
28. Poldermans D, Boersma E, Bax JJ, Thomson IR, van de Ven LL, Blankensteijn JD, Baars HF, Yo TI, Trocino G, Vigna C, Roelandt JR, van Urk H. The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group. The New England Journal of Medicine 1999 Dec;341(24):1789-94.
29. Ionescu DD; PREFER Investigators. Antihypertensive efficacy of perindopril 5–10 mg/day in primary health care: an open label, prospective, observational study. Clinical Drug Investigation 2009;29(12):767-76.
30. Ferrari R. Angiotensin-converting enzyme inhibition in cardiovascular disease: evidence with perindopril. Expert Review of Cardiovascular Therapy 2005 Jan;3(1):15-29.
31. Yalçin F, Aksoy FG, Muderrisoglu H, Sabah I, Garcia MJ, Thomas JD. Treatment of hypertension with perindopril reduces plasma atrial natriuretic peptide levels, left ventricular mass, and improves echocardiographic parameters of diastolic function. Clinical Cardiology 2000 Jun;23(6):437-41.
32. Asmar R, Topouchian J, Crisan O. Reversion of arterial abnormalities by long-term antihypertensive therapy in large population. The Compilor study. European Heart Journal 2000;21(Suppl):2366.
33. Dudarev MV, Odintsova NF, Vasiliev MYu, Nikolaeva AV. Clinical efficacy of Perindopril arginine in hypertensive patients with left ventricular hypertrophy. Arterial Hypertension 2010;16(6):542-8. (In Russian).
34. Campbell DJ. A Review of perindopril in the reduction of cardiovascular events. Vascular Health and Risk Management 2006;2(2):117-24.
35. DiNicolantonio JJ, O’Keefe JH. Perindopril for improving cardiovascular events. Vascular Health and Risk Management 2014 Aug;10:539-48.
36. Karpov YuA. Russian study PRIVILEGE: comparative efficacy of perindopril and enalapril in blood pressure control in patients with arterial hypertension. Systemic Hypertension 2008;10(2):12-5 (In Russian).
37. Hodzic E, Pecar E, Dzubur A, Smajic E, Hondo Z, Delic D, Rustempasic E. Efficacy and safety of perindopril in patients with essential hypertension. Materia SocioMedica 2020 Mar;32(1):4-9.
38. Tsoukas G, Anand S, Yang K; CONFIDENCE Investigators. Dose-dependent antihypertensive efficacy and tolerability of perindopril in a large, observational, 12-week, general practice-based study. American Journal of Cardiovascular Drugs 2011;11(1):45-55.
39. Fox KM; EURopean trial On reduction of cardiac events with perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). The Lancet. 2003;362(9386):782-8.
40. The PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering among 6105 individuals with previous stroke or transient ischaemic attack. The Lancet 2001 Sep;358(9287):1033-41.
41. Dahlöf B, Sever PS, Poulter NR, Wedel H, D Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O’Brien E, Ostergren J; ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial–Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. The Lancet 2005 Sep;366(9489):895-906.
42. Magrini G, Nicolosi GL, Chiariello M, Ferrari R, Remme P, Tavazzi L. [Rationale, characteristics and study design of PREAMI (Perindopril and Remodelling in the Elderly with Acute Myocardial Infarction]. Italian Heart Journal 2005 Nov;6(Suppl 7):14S-23S.
43. Vitovec J, Spinar J. First-dose hypotension after angiotensin-converting enzyme (ACE) inhibitors in chronic heart failure: a comparison of enalapril and perindopril. Slovak Investigator Group. European Journal of Heart Failure 2000 Sep;2(3):299-304.
44. Cleland JG, Tendera M, Adamus J, Freemantle N, Gray CS, Lye M, O’Mahony D, Polonski L, Taylor J. Perindopril for elderly people with chronic heart failure: the PEP-CHF study. The PEP investigators. European Journal of Heart Failure 1999 Aug;1(3):211-7.
45. Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J; PEP-CHF Investigators. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. European Heart Journal 2006 Oct;27(19):2338-45.
46. Del Colle S, Morello F, Rabbia F, Milan A, Naso D, Puglisi E, Mulatero P, Veglio F. Antihypertensive drugs and the sympathetic nervous system. Journal of Cardiovascular Pharmacology 2007 Nov;50(5):487-96.
47. Kobalava ZhD, Konradi AO, Nedogoda SV, Arutyunov GP, Baranova EI, Barbarash OL, Villevalde SV, Galyavich AS, Glezer MG, Drapkina OM, Kotovskaya YV, Libis RA, Lopatin YM, Nedoshivin AO, Ostroumova OD, Ratova LG, Tkacheva ON, Chazova IE, Chesnikova AI, Chumakova GA. Russian Society of Cardiology position paper on 2018 guidelines of the European Society of Cardiology/European Society of Arterial Hypertension for the management of arterial hypertension. Russian Journal of Cardiology 2018;23(12):131-42 (In Russian).
48. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009;338:b1665.
49. Bertrand ME, Ferrari R, Remme WJ, Simoons ML, Fox KM. Perindopril and β-blocker for the prevention of cardiac events and mortality in stable coronary artery disease patients: a European trial on Reduction Of cardiac events with Perindopril in stable coronary Artery disease (EUROPA) subanalysis. American Heart Journal 2015 Dec;170(6):1092-8.
50. Boytsov SA, Burtsev YP, Khomitskaya YV, Karpov YA; STYLE study investigators. Effectiveness and tolerability of the single-pill combination of bisoprolol and perindopril in patients with arterial hypertension and stable coronary artery disease in daily clinical practice: the STYLE study. Advances in Therapy 2021 Jun;38(6):3299-313.
51. Brugts JJ, Bertrand M, Remme W, Ferrari R, Fox K, MacMahon S, Chalmers J, Simoons ML, Boersma E. The treatment effect of an ACE-inhibitor based regimen with perindopril in relation to beta-blocker use in 29,463 patients with vascular disease: a combined analysis of individual data of ADVANCE, EUROPA and PROGRESS trials. Cardiovascular Drugs and Therapy 2017 Aug;31(4):391-400.
52. Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. The American Journal of Cardiology 1998 Oct;82(8A):2N-9N.
53. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. The Lancet 2002 Nov;360(9349):1903-13.
54. Hansson L, Lindholm LH, Ekbom T, Dahlöf B, Lanke J, Scherstén B, Wester PO, Hedner T, de Faire U. Antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish trial in old patients with hypertension-2 study. The Lancet 1999 Nov;354(9192):1751-6.
55. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. The Lancet 2002 Mar;359(9311):995-1003.
56. Gilyarevskiy SR, Golshmid MV, Kuzmina IM. Key drawbacks of secondary ischemic heart disease prevention with drug therapy: the role of combination fixed-dose preparations in solution of this problem. Kardiologiia 2018;58(11):17-23 (In Russian).
57. Libov IA, Moiseyeva YuN, Kondrashov OV. “Together we are stronger”: use of a fixed-dose combination of the β-blocker bisoprolol and the angiotensin-converting enzyme inhibitor perindopril arginine in the treatment of patients with arterial hypertension. Atmosphere. Cardiology News 2020;4:24-8 (In Russian).
58. Ostroumova OD, Kochetkov AI, Starodubova AV, Guseva TF. Novel combination of the angiotensin converting enzyme inhibitor perindopril and highly selective β-adrenoblocker bisoprolol: prime among the equal. Cardiovascular Therapy and Prevention 2018;17(3):85-95 (In Russian).
59. Strauss MH, Hall AS, Narkiewicz K. The combination of beta-blockers and ACE inhibitors across the spectrum of cardiovascular diseases. Cardiovascular Drugs and Therapy 2021 Sep 17. doi: 10.1007/s10557-021-07248-1. Online ahead of print.
  

[ Содержание выпуска N 1 | Выпуски журнала | Список журналов ]